RELB anticorps (AA 273-443)

N° du produit ABIN7539852

Cet anticorps Souris Monoclonal détecte spécifiquement RELB dans ELISA, IHC, FACS et ICC. Il présente une réactivité envers Humain.

Aperçu rapide pour RELB anticorps (AA 273-443) (ABIN7539852)

Antigène: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp RELB est non-conjugé

Application: ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunocytochemistry (ICC)

Clone: 2E4B1

Détail du produit anti-RELB anticorps

Épitope: AA 273-443

Fonction: RELB Antibody

Purification: Purified antibody

Immunogène: Purified recombinant fragment of human RELB (AA: 273-443) expressed in E. Coli.

Isotype: IgG2a

Information d'application

Indications d'application:

ELISA: 1/10000

FCM: 1/200 - 1/400

ICC: 1/200 - 1/1000

Restrictions: For Research Use only

Stockage

Buffer: Purified antibody in PBS with 0.05 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Détails sur RELB

Antigène: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Autre désignation: RELB

Sujet: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment

Poids moléculaire: 62.1 kDa

ID gène: 5971

UniProt: Q01201

Pathways: Signalisation NF-kappaB, Signalisation RTK